Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2011

01-04-2011 | Research Articles

Interleukin-15 enhances T-cell responses by stimulation with dendritic cells

Authors: Yu Zhao, Ke Cheng, Yang Wu, Xing-Chen Peng, Ye Chen, Ben-Xu Tan, Jun Ge, Hang Dong, Meng Wei, Feng Gao, Jing-Mei Su, Jian-Mei Hou, Ji-Yan Liu

Published in: Clinical and Translational Oncology | Issue 4/2011

Login to get access
Metadata
Title
Interleukin-15 enhances T-cell responses by stimulation with dendritic cells
Authors
Yu Zhao
Ke Cheng
Yang Wu
Xing-Chen Peng
Ye Chen
Ben-Xu Tan
Jun Ge
Hang Dong
Meng Wei
Feng Gao
Jing-Mei Su
Jian-Mei Hou
Ji-Yan Liu
Publication date
01-04-2011
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-011-0653-6

Other articles of this Issue 4/2011

Clinical and Translational Oncology 4/2011 Go to the issue

Research Articles

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)

Educational Series/Red Series

Recent advances in oncolytic virus design

Editorial

Pseudomyxoma peritonei: a rare disease and a disease model in peritoneal surface oncology

Research Articles

Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre

Special Article

Oncology outside hospital: a new experience for the benefit of longer survivors

Research Articles

Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits